نتایج جستجو برای: relapsing remitting multiple sclerosis
تعداد نتایج: 791996 فیلتر نتایج به سال:
Journal:
:Human Brain Mapping
2010
Journal:
:Biomedical Journal
2014
Journal:
:Archives of Clinical Neuropsychology
2007
Journal:
:Journal of Clinical Medicine
2019
Journal:
:CNS Drugs
2020
Journal:
:Neurologie pro praxi
2016
Journal:
:Arquivos de Neuro-Psiquiatria
1999
Journal:
:Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
2019
Journal:
:NeuroImage: Clinical
2015
Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies.
Journal:
:Archives of neurology
2007
Markus Krumbholz
Hannah Pellkofer
Ralf Gold
Lisa Ann Hoffmann
Reinhard Hohlfeld
Tania Kümpfel
BACKGROUND Natalizumab is a new therapeutic option for relapsing-remitting multiple sclerosis. As with other antibody therapies, hypersensitivity reactions have been observed. In the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) trial, infusion-related hypersensitivity reactions developed in 4% of patients, usually within 2 hours after starting the infusion....
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید